UO Ematologia, Casa Sollievo della Sofferenza
Welcome,         Profile    Billing    Logout  
 14 Trials 
20 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cascavilla, Nicola
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Hourglass May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL
Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum
Mantle Cell Lymphoma
05/21
05/26
NCT04168502 / 2019-003871-20: Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML

Recruiting
3
414
Europe
Gemtuzumab Ozogamicin
Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus, Pfizer S.R.L.
Acute Myeloid Leukemia
04/25
04/27
KRdvsRd, NCT04096066: A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant

Active, not recruiting
3
84
Europe
Carfilzomib, Kyprolis, Lenalidomide, Revlimid, Dexamethasone
Fondazione EMN Italy Onlus
Multiple Myeloma, New Diagnosis Tumor
01/26
01/26
DREAMM8, NCT04484623 / 2018-004354-21: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Jan 2024 - Dec 2024: Market entry for 2L multiple myeloma (based on DREAMM-7 trial)
Hourglass Oct 2024 - Dec 2024 : Acceptance of regulatory submission in US for 2L+ multiple myeloma
Hourglass Jul 2024 - Dec 2024 : Acceptance of regulatory submission in EU for 2L+ multiple myeloma (based on DREAMM-8 trial)
Jan 2024 - Dec 2024: Regulatory approval in US for 2L+ multiple myeloma (based on DREAMM-7 trial)
Jan 2024 - Dec 2024: Regulatory approval in EU for 2L+ multiple myeloma (based on DREAMM-7 trial)
More
Recruiting
3
357
Europe, Japan, US, RoW
Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib
GlaxoSmithKline
Multiple Myeloma
01/24
05/29
FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting
3
430
Europe
Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses
Fondazione Italiana Linfomi ONLUS, GRADE Onlus
Diffuse Large B-Cell Lymphoma, Elderly Patients
09/25
09/30
GIMEMA, NCT04722848 / 2020-006048-15: Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL

Recruiting
3
236
Europe
Ponatinib + Blinatumomab, Chemotherapy + Imatinib
Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus, Amgen S.r.l. via E. Tazzoli, 6 - 20154 - Milano, Incyte Biosciences International Sàrl, Rue Docteur-Yersin 10, 1110 Morges, Switzerland
Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult, Philadelphia-Positive ALL
09/27
09/27
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
07/28
07/30
ALL2418, NCT03610438 / 2018-003006-32: Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia

Recruiting
2a
76
Europe
Inotuzumab Ozogamicin (IO)
Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Lymphoid Leukemia
11/22
11/22
NCT04475731 / 2020-003912-28: Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse

Active, not recruiting
2
67
Europe
Ponatinib
Gruppo Italiano Malattie EMatologiche dell'Adulto, Incyte Biosciences International Sàrl, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus
Philadelphia-Positive ALL, Acute Lymphoblastic Leukemia, in Relapse
11/24
11/24
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

Active, not recruiting
2
75
Europe
Ibrutinib, IMBRUVICA (commercial name)
Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.
DLBCL
07/24
07/27
FIORELLA, NCT03495960 / 2016-003116-12: Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System

Completed
2
72
Europe
Rituximab, Methotrexate, Procarbazine, Lenalidomide, Radiotherapy, Temozolomide
International Extranodal Lymphoma Study Group (IELSG)
Primary Central Nervous System Lymphoma
12/24
12/24
CLL1818, NCT03804372 / 2019-000159-14: The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide

Terminated
2
5
Europe
Rituximab, Chemotherapy, Tenofovir alafenamide
Gruppo Italiano Malattie EMatologiche dell'Adulto
Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia
05/24
05/24
PV-ARC, NCT06134102: Clinical and Laboratory Characteristics of Polycythemia Vera

Completed
N/A
1150
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Polycythemia Vera
12/23
12/23
1621-QLG-LG, NCT03755856: Long-term Outcomes for Acute Myeloid Leukemia Patients

Recruiting
N/A
343
Europe, RoW
Questionnaire
Gruppo Italiano Malattie EMatologiche dell'Adulto, European Organisation for Research and Treatment of Cancer - EORTC
Acute Myeloid Leukemia
06/21
12/22
NCT03789981: Exploring Disease Immunogenicity and the Immunological Effects of Hypomethylating Agents in Acute Myeloid Leukemia

Active, not recruiting
N/A
75
Europe
Immunogenic profile
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Acute Myeloid Leukemia
12/24
12/25
CML1012, NCT01752062: Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors

Recruiting
N/A
148
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Myeloid Leukemia, Pregnancy
12/22
12/22
NCT04460950: Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms

Recruiting
N/A
237
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia, Familial Acute Myeloid Leukemia, Myelodysplastic Syndromes
03/25
03/25
MY MYELOMA, NCT05001087: A "Physician & Patient-powered" Cohort Registry

Recruiting
N/A
1900
Europe
Observation
Fondazione EMN Italy Onlus
Multiple Myeloma
03/24
03/24
NCT04460963: Role of Adrenomedullin in Leukemic Endosteal/Vascular Niches

Recruiting
N/A
72
Europe
Adrenomedullin
Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia
06/24
06/24
CLARITY, NCT03190525: Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma

Recruiting
N/A
520
Europe
Quality of life questionnaires
Gruppo Italiano Malattie EMatologiche dell'Adulto
Multiple Myeloma
12/24
12/24

Download Options